**Author details**

Bin Liu1 , Zhangbao Wu1 , Ting Liu2 , Rui Qian2 , Tingni Wu2 , Qingchuan Liu3 and Aizong Shen1 \*

\*Address all correspondence to: aizongshen@163.com

1 Department of Pharmacy, Anhui Provincial Hospital, Hefei, Anhui Province, China

2 School of Pharmacy, Anhui Medical University, Hefei, Anhui Province, China

3 School of Biomedical Engineering, Hefei University of Technology, Hefei, Anhui Province, China

[10] Wang N, Wang T. Preparation of multifunctional liposomes as a stable vaccine deliveryadjuvant system by procedure of emulsification-lyophilization. Methods in Molecular

Polymeric Nanoparticles Engineered as a Vaccine Adjuvant-Delivery System

http://dx.doi.org/10.5772/intechopen.81084

41

[11] Kammona O, Bourganis V, Karamanidou T, Kiparissides C. Recent developments in nanocarrier-aided mucosal vaccination. Nanomedicine (London, England). 2017;**12**(9):1057-1074

[12] Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, et al. Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors.

[13] Bachmann MF, Jennings GT. Vaccine delivery: A matter of size, geometry, kinetics and

[14] Schottler S, Becker G, Winzen S, Steinbach T, Mohr K, Landfester K, et al. Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated

[15] Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: Effect

[16] Al-Barwani F, Donaldson B, Pelham SJ, Young SL, Ward VK.Antigen delivery by virus-like particles for immunotherapeutic vaccination. Therapeutic Delivery. 2014;**5**(11):1223-1240

[17] Shirbaghaee Z, Bolhassani A. Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems. Biopolymers. 2016;**105**(3):113-132

[18] Westerhoff M, Ahn J. Chronic hepatitis C and direct acting antivirals. Surgical Pathology

[19] Earnest-Silveira L, Christiansen D, Herrmann S, Ralph SA, Das S, Gowans EJ, et al. Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle

[20] Christiansen D, Earnest-Silveira L, Chua B, Meuleman P, Boo I, Grubor-Bauk B, et al. Immunological responses following administration of a genotype 1a/1b/2/3a quadriva-

[21] Boucher CA, Bobkova MR, Geretti AM, Hung CC, Kaiser R, Marcelin AG, et al. State of the art in HIV drug resistance: Science and technology knowledge gap. AIDS Reviews.

[22] Gao Y, McKay PF, Mann JFS. Advances in HIV-1 vaccine development. Viruses.

[23] Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. The

[24] Karnasuta C, Akapirat S, Madnote S, Savadsuk H, Puangkaew J, Rittiroongrad S, et al. Comparison of antibody responses induced by RV144, VAX003, and VAX004 vaccination

molecular patterns. Nature Reviews. Immunology. 2010;**10**(11):787-796

nanocarriers. Nature Nanotechnology. 2016;**11**(4):372-377

of dose. Biochimica et Biophysica Acta. 1991;**1068**(2):133-141

vaccine. Journal of Virological Methods. 2016;**236**:87-92

lent HCV VLP vaccine. Scientific Reports. 2018;**8**(1):6483

New England Journal of Medicine. 2009;**361**(23):2209-2220

regimens. AIDS Research and Human Retroviruses. 2017;**33**(5):410-423

Biology. 2016;**1404**:635-649

Clinics. 2018;**11**(2):287-296

2018;**20**(1):27-42

2018;**10**(4):167-175

Journal of Immunology. 2004;**173**(5):3148-3154
